510(k) Report

510(k) · Cleared

Cleared

Modification to Synchron Systems Benzodiazepine Reagent

K023048510(k) SpecialCleared Nov 7, 200255-day reviewClass II21 CFR 862.3170

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Beckman Coulter, Inc. · JXM Enzyme Immunoassay, Benzodiazepine

Cleared on Nov 7, 2002 as substantially equivalent to K944076 (Beckman Instruments, Inc., 1994) after a 55-day review. Its family tree reaches back 1 generation to 1994. 2 later devices descend from it.

Decided
Nov 7, 2002
Review
55 days
Class
Class II
Product code
JXM
Recalls
None
Predicates
1

Its longest line of descent runs back 1 generation to K944076 (1994). 2 later devices descend from it, 2 citing it directly.

Descendants, by year cleared 2005: 2 descendants clearedK944076 · CX (TM) Benzodiazepine (Benz) Reagent for Sychron CX Sys · Beckman Instruments, Inc. · 19941990200020102020
Descendants, by generation 1 generation forward: 2 descendants K944076 · CX (TM) Benzodiazepine (Benz) Reagent for Sychron CX Sys · Beckman Instruments, Inc. · 19940
  1. Root · 1 generation backK944076 CX (TM) Benzodiazepine (Benz) Reagent for Sychron CX SysBeckman Instruments, Inc. · 1994
  2. This deviceK023048 Modification to Synchron Systems Benzodiazepine ReagentBeckman Coulter, Inc. · 2002
  3. Descendant · cites it directly · 0 of its ownK051307 Synchron Systems Bebzodiazapine (Ebnz) ReagentBeckman Coulter, Inc. · 2005
  4. Descendant · cites it directly · 0 of its ownK043556 Synchron Systems Benzodiazepine (BNZG) ReagentBeckman Coulter, Inc. · 2005

Most influential descendants

Showing 2 of 2 · See all
  • K051307Synchron Systems Bebzodiazapine (Ebnz) ReagentBeckman Coulter, Inc. · 2005 · cites it directly0descendants
  • K043556Synchron Systems Benzodiazepine (BNZG) ReagentBeckman Coulter, Inc. · 2005 · cites it directly0descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−1K944076CX (TM) Benzodiazepine (Benz) Reagent for Sychron CX SysBeckman Instruments, Inc.1994—
0 (this device)K023048Modification to Synchron Systems Benzodiazepine ReagentBeckman Coulter, Inc.2002—
+1K051307Synchron Systems Bebzodiazapine (Ebnz) ReagentBeckman Coulter, Inc.2005—
+1K043556Synchron Systems Benzodiazepine (BNZG) ReagentBeckman Coulter, Inc.2005—

Descendants by year cleared

Year clearedDevicesWith a Class I recall
200520
FIG. 1 — Lineage of K023048, 1994–2005Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in JXM? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new JXM device

  1. #1 K243498 Alinity c Benzodiazepines Reagent Kitscore 8.8 · 2 generations · no Class I recall
  2. #2 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K944076CX (TM) Benzodiazepine (Benz) Reagent for Sychron CX Sys
Summary page 1
…iazepine Reagent claims substantial equivalence to the SYNCHRON Systems Benzodiazepine Reagent currently in commercial distribution. (FDA 51O(k) Number K944076) 5.0 Device Description The SYNCHRON Systems Benzodiazepine (BENZ) reagent is designed for optimal perfo…
Beckman Instruments, Inc.1994—

What descends from it? (2)

2 later devices cite it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K051307Synchron Systems Bebzodiazapine (Ebnz) ReagentBeckman Coulter, Inc.20050
K043556Synchron Systems Benzodiazepine (BNZG) ReagentBeckman Coulter, Inc.20050

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • Its one ancestor has no recall.
  • Of its descendants, K051307 (Beckman Coulter, Inc., 2005) has gone furthest, with 0 descendants of its own.

How does its category compare?

All JXM devices

JXM Enzyme Immunoassay, Benzodiazepine: FDA decisions, review times, recalls and adverse event reports over 20 years.

FDA decisions per year · JXM

1in 2024

2010: 12011: 12012: 12015: 22016: 22017: 22018: 12019: 12022: 12024: 1
2007high 2 (2015) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · JXM

Too few JXM 510(k)s in any year since 2007 to give a median.

Recalls per year · JXM

79in 2015

2015: 79
2007high 79 (2015) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · JXM

6in 2025

2008: 32009: 12010: 32011: 32012: 12013: 32014: 32015: 52016: 22017: 42018: 42019: 32021: 12023: 52024: 62025: 6
2007high 6 (2024) · low 0 (2007)2025

MAUDE reports naming product code JXM, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—03
20090—01
20101—03
20111—03
20121—01
20130—03
20140—03
20152—795
20162—02
20172—04
20181—04
20191—03
20200—00
20210—01
20221—00
20230—05
20241—06
20250—06
20260—0—

What is it indicated for?

Benzodiazepine (BENZ) Reagent, in conjunction with SYNCHRON® Systems Drugs of Abuse Testing (DAT) Urine Calibrators, is intended for the qualitative determination of benzodiazepines in human urine at a cutoff value of 200 ng/mL, on SYNCHRON Systems. The Benzodiazepine assay provides a rapid screening procedure for determining the presence of benzodiazepines in urine. This test provides only a preliminary analytical result; a positive result by this assay…

Read the full statement (117 words)

Benzodiazepine (BENZ) Reagent, in conjunction with SYNCHRON® Systems Drugs of Abuse Testing (DAT) Urine Calibrators, is intended for the qualitative determination of benzodiazepines in human urine at a cutoff value of 200 ng/mL, on SYNCHRON Systems.

The Benzodiazepine assay provides a rapid screening procedure for determining the presence of benzodiazepines in urine. This test provides only a preliminary analytical result; a positive result by this assay should be confirmed by another generally accepted non-immunological method, such as thin layer chromatography (TLC), gas chromatography (GC), or gas chromatography/mass spectrometry (GC/MS). GC/MS is the preferred confirmatory method.

Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K023048: Modification to Synchron Systems Benzodiazepine Reagent.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K023048

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026